Intracerebral microdialysis technique and its application on brain pharmacokinetic-pharmacodynamic study

Archives of Pharmacal Research

Volumn 30, Issue 12, 2007, Pages 1635-1645

  Pan, Yue Fang ^a   Feng, Jian ^a   Cheng, Qiao Yuan ^a   Li, Fan Zhu ^a  

^a ZHEJIANG CHINESE MEDICAL UNIVERSITY   (China)

Author keywords

Analgesic drug; Antidepressant drug; Antiepileptic drug; Extracellular fluid; Intracerebral microdialysis; Pharmacokinetic pharmacodynamic

Indexed keywords

EID: 38049186780     PISSN: 02536269     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02977335     Document Type: Review

References (67)

1. Apelqvist, G., Wikell, C., Carlsson, B., Hjorth, S., Bergqvist, P. B., Ahlner, J., and Bengtsson, F., Dynamic and kinetic effects of chronic citalopram treatment in experimental hepatic encephalopathy. Clin. Neuropharmacol., 23, 304-317 (2000).
2. Alfinito, P. D., Huselton, C., Chen, X., and Deecher. D. C., Pharmacokinetic and pharmacodynamic profiles of the novel serotonin and norepinephrine reuptake inhibitor desvenlafaxine succinate in ovariectomized Sprague-Dawley rats. Brain Res., 1098, 71-78 (2006).
3. Ahmad, S., Fowler, L. J., and Whitton, P. S., Effects of combined lamotrigine and valproate on basal and stimulated extracellular amino acids and monoamines in the hippocampus of freely moving rats. Naunyn-Schmiedebergs. Arch. Pharmacol., 371, 1-8 (2005).
4. Breimer, D. D. and Danhof, M., Relevance of the application of pharmacokinetic-pharmacodynamic modeling concepts in drug development. The "Wooden Shoe" paradigm. Clin. Pharmacokin., 32, 259-267 (1997).
5. Brunner, M. and Langer, O., Microdialysis versus other techniques for the clinical assessment of in vivo tissue drug distribution. AAPS J., 8, E263-E272 (2006).
6. Bouw, M. R., Xie, R., Tunblad, K., and Hammarlund-Udenaeas M., Blood-brain barrier transport and brain distribution of morphine-6-glucuronide in relation to the antinociceptive effect in rats-pharmacokinetic/ pharmacodynamic modelling. Br. J. Pharmacol., 134, 1796-1804 (2001).
7. Bouw, M. R., Gardmark, M., and Hammarlund-Udenaes, M., Pharmacokinetic-pharmacodynamic modelling of morphine transport across the blood-brain barrier as a cause of the antinociceptive effect delay in rats - a microdialysis study. Pharm. Res., 17, 1220-1228 (2000).
8. Bush, M. A. and Pollack, G. M., Pharmacokinetics and Pharmacodynamics of 7-Nitroindazole, a Selective Nitric Oxide Synthase Inhibitor in the Rat Hippocampus. Pharm. Res., 18, 1607-1612 (2001).
9. Berqqvist, P. B., Wikell, C., Hjorth, S., Bergqvist, P. B., Apeldqvist, G., and Bengtsson, F., Effect of citalopram on brain serotonin release in experimental hepatic encephalopathy: implications for thymoleptic drug safety in liver insufficiency. Clin. Neuropharmacol., 20, 511-522 (1997).
10. Bymaster, F. P., Lee, T. C., Knadler, M. P., Detke, M. J., and Ivenqar, S., The dual transporter inhibitor duloxetine: a review of its preclinical pharmacology, pharmacokinetic profile, and clinical results in depression. Curr. Pharm. Des., 11, 1475-1493 (2005).
11. Bundgaard, C., Jorqensen, M., and Mork, A., An integrated microdialysis rat model for multiple pharmacokinetic/pharmacodynamic investigations of serotonergic agents. J. Pharmacol. Toxicol. Methods., 55, 214-223 (2006).
12. Bickel, U., How to measure drug transport across the blood-brain barrier. NeuroRx., 2, 15-26 (2005).
13. Boschi, G. and Scherrmann, J., Microdialysis in mice for drug delivery research. Adv. Drug Deliv. Rev., 45, 271-281 (2000).
14. Bourne, J. A., Intracerebral microdialysis: 30 years as a tool for the neuroscientist. Clin. Exp. Pharmacol. Physiol., 30, 16-24 (2003).
15. Benturquia, N., Parrot, S., Sauvinet, V., Renaud, B., and Denoroy, L., Simultaneous determination of vigabatrin and amino acid neurotransmitters in brain microdialysates by capillary electrophoresis with laser-induced fluorescence detection. J. Chromatogr. B. Analyt. Technol. Biomed. Life. Sci., 806, 237-244 (2004).
16. Chenel, M., Marchand, S., Dupuis, A., Lamarche, I., Paquereau, J., Pariat, C., and Couet, W., Simultaneous central nervous system distribution and pharmacokinetic-pharmacodynamic modelling of the electroencephalogram effect of norfloxacin administered at a convulsant dose in rats. Br. J. Pharmacol., 142, 323-330 (2004).
17. Cuadrado, A., Bravo, J., and Armijo, J. A., Synergistic interaction between felbamate and lamotrigine against seizures induced by 4-aminopyridine and pentylenetetrazole in mice. Eur. J. Pharmacol., 465, 43-52 (2003).
18. Cunningham, M. O. and Jones, R. S., The anticonvulsant lamotrigine decreases spontaneous glutamate release but increases spontaneous GABA release in the rat entorhinal cortex in vivo. Neuropharmacology, 39, 2139-2141 (2000).
19. Cleton, A., Altorf, B. A., Voskuyl, R. A., and Danhof, M., Effect of amygdala kindling on the central nervous system effects of tiagabine: Effects versus brain GABA levels. Br. J. Pharmacol., 130, 1037-1044 (2000).
20. Clinckers, R., Smolders, I., Meurs, A., Ebinger, G., and Michotte, Y., Hippocampal dopamine and serotonin elevations as pharmacodynamic markers for the anticonvulsant efficacy of oxcarbazepine and 10,11-dihydro-10- hydroxycarbamazepine. Neurosci. Lett. 390, 48-53 (2005a).
21. Clinckers, R., Smolders, I., Meurs, A., Ebinger, G., and Michotte, Y., Quantitative in vivo microdialysis study on the influence of multidrug transporters on the blood-brain barrier passage of oxcarbazepine: conconmitant use of hippocampal monoamine as pharmacodynamic markers for the anticonvulsant activity. J. Pharmacol. Exp. Ther., 314, 725-731 (2005b).
22. Dash, A. K. and Elmquist, W. F., Separation methods that are capable of revealing blood-brain barrier permeability. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci., 797, 241-254 (2003).
23. Delgado, J. M., DeFeudis, F. V., Roth, R. H., Ryugo, D. K., and Mitruka, B. M., Dialytrode for long term intracerebral perfusion in awake monkeys. Arch. Int. Pharmacodyn. Ther., 198, 9-21 (1972).
24. Danhof, M., Alvan, G., Dahl, S. G., Kuhlmann, J., and Paintaud, G., Mechanism-based pharmacokinetic/pharmacodynamic modeling - a new classification of biomarkers. Pharm. Res., 22, 1432-1437 (2005).
25. Davies, M. I., Cooper, J. D., Desmond, S. S., Lunte, C. E., and Lunte, S. M., Analytical considerations for microdialysis sampling. Adv. Drug Deliv. Rev., 45, 169-188 (2000).
26. D'Souza, M. S. and Duvauchelle, C. L., Comparing nucleus accumbens and dorsal striatal dopamine responses to self-administered cocaine in naive rats. Neurosci. Lett., 408, 146-150 (2006).
27. de Lang, E. C., Danhof, M., de Boer, A.G., and Breimer, D. D., Methodological considerations of intracerebral microdialysis in pharmacokinetic studies on drug transport across the blood-brain barrier. Brain Res. Rev., 25, 27-49(1997).
28. de Lang E. C., Ravenstijn P. G., Groenendaal D., and van Steeg T. J., Toward the prediction of CNs drug-effect profiles in physiological and pathological conditions using MD and mechanism-based pharmacokinetic- pharmacodynamic modeling. AAPS J., 7, E532-E543 (2005).
29. Ferrer, A. and Artiqas, F., Effects of single and chronic treatment with tranylcypromine on extracellular serotonin in rat brain. Eur. J. Pharmacol., 263, 227-34 (1994).
30. Feelisch, M., Biotransformation to nitric oxide of organic nitrates in comparison to other nitrovasodilators. Eur. Heart J., 14, 123-132 (1993).
31. Greig, N. H., De, Micheli. E., Holloway, H. W., Yu, Q. S., Utsuki, T., Perry, T. A., Brossi, A., Ingram, D. K., Deutsch, J., Lahiri, D. K., and Soncrant, T. T., The experimental Alzheimer drug phenserine: preclinical pharmacokinetics and pharmacodynamics. Acta. Neurol. Scand. Suppl., 176, 74-84 (2000).
32. Groenendaal, D., Blom-Roosemalen, M. C., Danhof, M., and Lange, E. C., High-performance liquid chromatography of nalbuphine, butorphanol and morphine in blood and brain microdialysate samples: application to pharmacokinetic/ pharmacodynamic studies in rats. J. Chromatogr. B. Analyt. Technol. Biomed. Life. Sci., 822, 230-237 (2005).
33. Gatto, G. J. , Bohme, G. A., Caldwell, W. S., Letchworth, S. R., Traina, V. M., Obinum, M. C., Laville, M., Reibaud, M., Pradier, L., Dunbar, G., and Bencherif, M., TC-1734: an orally active neuronal nicotinic acetylcholine receptor modulator with antidepressant neuroprotective and long-lasting cognitive effects. CNS. Drug. Rev., 10, 147-166 (2004).
34. Horn, T. F. and Engelmann, M., In vivo microdialysis for nonapeptides in rat brain - a practical guide, Methods, 23,41-53 (2001).
35. Hernandez, L., Stanley, B. G., and Hoebel, B. G., A small, removable microdialysis probe. Life. Sci., 39, 2629-2637 (1986).
36. Hernandez, L. and Hoebel, B. G., Haloperidol given chronically decreases basal dopamine in the prefrontal cortex more than the striatum or nucleus accumbens as simultaneously measured by microdialysis. Brain Res. Bull., 22, 763-769 (1989).
37. Heinzen, E. L. and Pollack, G. M., Pharmacodynamics of morphine-induced neuronal nitric oxide production and antinociceptive tolerance development. Brain Res., 1023, 175-184 (2004).
38. Hedava, M. A. and Pan W. J., Cocaine pharmacokinetics/pharmacodynamics in awake freely moving rats. Pharm. Res., 14, 1099-1113 (1997).
39. Ichikawa, J., Kuroki, T., and Meltzer, H. Y., Differential effects of chronic imipramine and fluoxetine on basal and amphetamine-induced extracellular dopamine levels in rat nucleus accumbens. Eur. J. Pharmacol., 350, 159-164 (1998).
40. Jacobson, I., Sandberg, M., and Hamberger, A., Mass transfer in brain dialysis devices - a new method for the estimation of extracellular amino acids concentration. J. Neurosci. Methods, 15, 263-268 (1985).
41. Jonker, D. M., Visser, S. A., Graaf, P. H., Voskuyl, R. A., and Danhof, M., Towards a mechanism-based analysis of pharmacodynamic drug-drug interactions in vivo. Pharmacol. Ther., 106, 1-18 (2005).
42. Khan, S. H. and Shuaib, A., The technique of intracerebral microdialysis. Methods, 23, 3-9 (2001).
43. Lonnroth, P., Jansson P. A., and Smith U., A microdialysis method allowing characterization of intercellular water space in humans. Am. J. Physiol., 253, E228-E231 (1987).
44. Larsson, C. I., The use of an "internal standard" for control of the recovery in microdialysis. Life Sci., 49, PL73-PL78 (1991).
45. Landgraf, R., Neumann, I., Russel, J. A., and Pittman, Q. J., Push-pull perfusion and microdialysis studies of central oxytocin and vasopressin release in freely moving rats during pregnancy, parturition, and lactation. Ann. N. Y. Acad. Sci., 652, 326-339 (1992).
46. 125Icobrotoxin after intranasal administration to the brain: A microdialysis study in freely moving rats. Int. J. Pharm., 328, 161-167 (2007).
47. Li, Y., Peris, J., Zhong, L., and Derendorf, H., Microdialysis as a tool in local pharmacodynamics. AAPS J., 8, E222-E235 (2006).
48. Mano, Y., Hiquchi, S., and Kamimura, H., Investigation of the high partition of YM992, a novel antidepressant, in rat brain - in vitro and in vivo evidence for the high binding in brain and the high permeability at the BBB. Biopham. Drug Dispos., 23, 351-360 (2002).
49. Netigh, G. N., Arnold, H. M., Rabenstein, R. L., Sarter, M., and Bruno, J. P., Neuronal activity in the nucleus accumbens is necessary for performance-related in cortical acetylcholine release. Neuroscience, 123, 635-645 (2004).
50. Obrenovitch, T. P., Urenjak, J., Richards, D. A., Ueda, Y., Curzon, G., and Symon, L., Extracellular neuroactive amino acids in the rat brain striatum during ischaemia: comparison between penumbral conditions and ischaemia with sustained anoxic depolarisation. J. Neurochem., 61,178-186 (1993).
51. Orlowska-Majdak M., Microdialysis of the brain structures: application in behavioral research on vasopressin and oxytocin. Acta. Neurobiol. Exp.(Wars), 64,177-188 (2004).
52. Plock, N. and Kloft, C., Microdialysis - theoretical background and recent implementation in applied life-sciences. Eur. J. Pharm. Sci., 25, 1-24 (2005).
53. Peerdeman, S. M., Girbes, A. R., and Vandertop, W. P., Cerebral microdialysis as a new tool for neurometabolic monitoring. Intensive Care. Med., 26, 662-669 (2000).
54. Stahl, M., Bouw R., Jackson A., and Pay V., Human microdialysis. Curr. Pharm. Biotechnol., 3, 165-178 (2002).
55. Swanson, C. J., Perry, K. W., Koch-Krueger, S., Katner, J., Svensson, K. A., and Bvmaster, F. P., Effect of the attention deficit/hyperactivity disorder drug atomoxetine on extracellular concentrations of norepinephrine and dopamine in several brain regions of the rat. Neuropharmacology, 50, 755-760 (2006).
56. Tsai, T. H., Assaying protein unbound drugs using microdialysis techniques. J. Chromatogr. B. Analyt. Technol. Biomed. Life. Sci., 797, 161-173 (2003).
57. Ungerstedt, U., Microdialysis - principles and applications for studies in animals and man. J. Intern. Med., 230, 365-373 (1991).
58. Ungerstedt, U. and Pycock, C., Functional correlates of dopamine neurotransmission. Bull. Schweiz. Akad. Med. Wiss., 30, 44-55 (1974).
59. Vezzani, A., Ungerstedt, U., French, E. D., and Schwarcz, R., In vivo brain dialysis of amino acids and simultaneous EEG measurements following intrahippocampal quinolinic acid injection: evidence for a dissociation between neurochemical changes and seizures. J. Neurochem., 45, 335-344 (1985).
60. Westerink B. H., Brain microdialysis and its application for the study of animal behaviour. Behav. Brain Res., 70, 130-124 (1995).
61. Weikop, P., Eqestad, B., and Kehr, J., Application of triple-probe microdialysis for fast pharmacokinetic/pharmacodynamic evaluation of dopamimetic activity of drug candidates in the rat brain. J. Neurosci. Methods, 140, 59-65 (2004).
62. Wikell, C., Apelqvist, G., Hjorth, S., Kullingsjo, J., Bergqvist, P. B., and Bengtsson, F., Effects on drug disposition, brain monoamines and behavior after chronic treatment with the antidepressant venlafaxine in rats with experimental hepatic encephalopathy. Eur. Neuropsychopharmacol., 12, 327-336 (2002).
63. Wikell, C., Kugelberg F. C., Hjorth, S., Apeldqvist, G., and Bengtsson, F., Effect of halving the dose of venlafaxine to adjust for putative pharmacokinetic and pharmacodynamic changes in an animal model of chronic hepatic encephalopathy. Clin Neuropharmacal, 24, 324-333 (2001a).
64. Wikell, C., Hjorth, S., Apeldqvist, G., Kullingsjo, J., Lundmark, J., Bergqvist, P. B., and Bengtsson, F., Sustained administration of the antidepressant venlafaxine in rats: pharmacokinetic and pharmacodynamic findings. Naunyn Schmiedebergs Arch Pharmacol., 363, 448-455 (2001b).
65. Wong, D. T., Duloxetine (LY 248686): an inhibitor of serotonin and noradrenaline uptake and an antidepressant drug candidate. Expert. Opin. Investig. Drugs, 7, 1691-1699 (1998).
66. Yassen, A., Olofsen, E., Dahan, A., and Danhof M., Pharmacokinetic- pharmacodynamic modeling of the antinociceptive effect of buprenorphine and fentanyl in rats: role of receptor equilibration kinetics. J. Pharmacol. Exp. Ther., 313,1136-1149 (2005).
67. Zhou, Q. and Gallo, J. M., In vivo microdialysis for PK and PD studies of anticancer drugs. AAPS J., 7, E659-E667 (2005).